Cardio Diagnostics Holdings (CDIO) Common Equity (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Common Equity of $8.9 million for Q1 2026, up 27.68% sequentially from $7.0 million in Q4 2025, and down 21.74% YoY from $11.4 million in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Common Equity (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Common Equity for 6 years, with the latest figure at $8.9 million in Q1 2026.
- Quarterly Common Equity fell 21.74% year-over-year to $8.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.9 million (down 21.74% YoY) and the FY2025 annual result came in at $7.0 million, down 27.04% from the prior year.
- Common Equity grew to $8.9 million in Q1 2026 per CDIO's latest filing, from $7.0 million in the prior quarter.
- Over five years, Common Equity peaked at $11.4 million in Q1 2025 and troughed at $778054.0 in Q1 2022.
- A 5-year average of $5.9 million and a median of $4.3 million in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2023: Common Equity surged 39337.4% in 2022, then slumped 76.1% in 2023.
- Over 5 years, Common Equity stood at $4.3 million in 2022, then plunged by 31.23% to $3.0 million in 2023, then surged by 223.1% to $9.6 million in 2024, then fell by 27.04% to $7.0 million in 2025, then climbed by 27.68% to $8.9 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $8.9 million, $7.0 million, and $8.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.79 Bn |
| 10 | Cardio Diagnostics Holdings | 6.07 Mn | 480,214.31 | - | 7.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.43 Mn |
| Mar 31, 2026 | 8.90 Mn |
| Dec 31, 2025 | 6.97 Mn |
| Sep 30, 2025 | 8.15 Mn |
| Jun 30, 2025 | 9.72 Mn |
| Mar 31, 2025 | 11.38 Mn |
| Dec 31, 2024 | 9.56 Mn |
| Sep 30, 2024 | 3.69 Mn |
| Jun 30, 2024 | 3.07 Mn |
| Mar 31, 2024 | 3.04 Mn |
| Dec 31, 2023 | 2.96 Mn |
| Sep 30, 2023 | 2.29 Mn |
| Jun 30, 2023 | 2.91 Mn |
| Mar 31, 2023 | 3.42 Mn |
| Dec 31, 2022 | 4.30 Mn |
| Sep 30, 2022 | 9.57 Mn |
| Jun 30, 2022 | 9.70 Mn |
| Mar 31, 2022 | 778,054.00 |
| Dec 31, 2021 | 1.07 Mn |
| Sep 30, 2021 | 24,279.00 |